Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2T Safra, F Muggia, S Jeffers, et al.
Cancer|February 15, 1986
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neckS E Vogl, A Komisar, B H Kaplan, et al.
Investigational New Drugs|January 1, 1985
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancerJ M Bennett, P Byrne, A Desai, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1987
Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimenM J Piccart, J L Speyer, J C Wernz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapyS Demaria, M D Volm, R L Shapiro, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 26, 1999
MDR1 gene expression in primary and advanced breast cancerX Yang, B Uziely, S Groshen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepiloneS Mani, H M McDaid, A Grossman, et al.
Gynecologic Oncology|November 28, 2006
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignanciesM V Seiden, H A Burris, U Matulonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2012
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancerC F Verschraegen, S Czok, C Y Muller, et al.
La Nouvelle Presse Medicale|March 31, 1979
[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]M Hayat, M Bayssas, G Brulé, et al.
Pageof 6